News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
DealTalk: Battle for Actelion may be Rerun of Genzyme Saga
November 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Jean-Paul Clozel, the ex-Roche (ROG.VX) scientist who founded Actelion (ATLN.VX) in 1997, is digging in to defend the Swiss biotech company in a battle that could mirror the fight for control of Genzyme (GENZ.O).
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Layoffs
Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs
September 18, 2025
·
9 min read
·
Angela Gabriel
Europe
AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility
September 15, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
·
1 min read
·
Lori Ellis
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
·
3 min read
·
Annalee Armstrong